Shares of Nektar Therapeutics surged more than 19% in early Monday trading on April 20, 2026, climbing $16.58 to $101.44 as investors cheered positive 52-week topline results from the Phase 2b REZOLVE-AA clinical trial of the company's lead immunology candidate, rezpegaldesleukin, in patients with severe-to-very-severe alopecia areata.
The biotechnology company, focused on developing novel therapies that stimulate regulatory T cells to treat autoimmune and inflammatory diseases, released the data ahead of an investor conference call scheduled for 8 a.m. ET. The extension period results demonstrated a deepening of clinical responses over time, with sustained hair regrowth and improved SALT (Severity of Alopecia Tool) scores in treated patients.
